PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumorsPLN-101095 accelerated ...

In a significant breakthrough in reproductive medicine, doctors at a private hospital in New Delhi have reported two successful live births after treating severe Asherman's Syndrome using umbilical ...

Doctors in New Delhi have achieved two successful live births by treating severe Asherman's Syndrome with umbilical cord-derived stem cells. The pioneering procedure offers new hope to women suffering ...

NorthStrive Fund II LP ("NorthStrive Fund", "we", "our" or "us"), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, is a significant shareholder of Bluejay ...

Glo-BNHL global trial opens sites in Netherlands and Austria to trial multiple new treatments for B-cell Non-Hodgkin Lymphoma ...

Mezigdomide plus carfilzomib and dexamethasone improves progression free survival in patients with relapsed or refractory multiple myeloma. Positive interim results were announced from a phase 3 trial ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Initial clinical response data for AlloNK in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial ...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b ...

Johnson & Johnson JNJ announced that it has submitted a type II variation application to the European Medicines Agency (EMA) seeking approval for the expanded use of Tecvayli (teclistamab). The ...

Selection of tech transfer partner follows Tempest’s recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% CR in all six efficacy ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer.